Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limite

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information dissemi

Host: Deborah Siegal, MD, MSc, FRCPC The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information dissemin

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information dissemi

Host: Craig I. Coleman, PharmD, FASHP Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-eme

Host: Jan Beyer-Westendorf, MD, PhD The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information dissemina

Guest: Candace T. Westgate, DO, MPH, FACOG Guest: Ethan D. Schram, MD, FACP Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy,

Guest: James Galvin, MD, MPH, FANA Guest: Jon Toledo, MD, PhD Guest: Charles P. Vega, MD Recently, Alzheimers Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (A) targeting DMT now a reality,

Host: Gregory J. Fermann, MD Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixa